[C-terminal 30 bp-deletion mutation of latent membrane protein 1 gene of Epstein-barr virus in non-hodgkin's lymphoma].
Epstein-Barr virus (EBV) is associated with genesis of many human tumors, including non-Hodgkin's lymphoma (NHL). Latent membrane protein 1 (LMP1) gene is considered as an oncogene of EBV. Recent researches have suggested that LMP1 polymorphisms, especially C-terminal 30bp-deletion (del-LMP1), might be associated with carcinogenicity of EBV, and play important roles in tumorigenesis. This study was to detect expression of del-LMP1 gene in NHL patients and healthy people, and explore relationship of del-LMP1 gene to tumorigenesis and prognosis of NHL. LMPl gene segments (including the 30 bp deletion) in 48 NHL patients and 60 healthy people were amplified by polymerase chain reaction (PCR) with sequence-specific primers. PCR products were randomly chosen,and sequenced to confirm their specificities and to detect other mutations of LMP1 gene. The distributions of del-LMPl in NHL patients and healthy people were compared. Relationship of del-LMP1 gene to prognosis of NHL was analyzed. (1) LMP1 gene was detected in 23 of 48 NHL patients, 18 of 23 (78%) harbored del-LMPl; LMP1 gene was detected in 32 of 60 healthy people, 13 of 32 (41%) harbored del-LMPl. Positive rate of del-LMPl gene in NHL patients was significantly higher than that in healthy people (P < 0.05). (2) Among 23 EBV-related NHL patients, 15 belonged to high risk group (IPI>/=3), and del-LMPl was detected in 14 of them (93%); 8 belonged to low risk group (IPI<3), and del-LMPl was detected in 4 of them (50%). Positive rate of del-LMP1 in IPI>/=3 group was significantly higher than that in IPI < 3 group (P<0.05). (3)Sequencing confirmed that the 30 bp-deletion located at 168 285-168 256 nt (355-346 aa), and most C-terminal mutations located at 168 357-168 225 nt. Del-LMPl gene exists commonly in EBV-related NHL, and might correlate with prognosis of NHL.